Gender-Specific Efficacy Revealed by Head-to-Head Comparison of Pasireotide and Octreotide in a Representative In Vivo Model of Nonfunctioning Pituitary Tumors

Clicks: 205
ID: 272358
2021
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #45 of 68 articles by views in Cancers

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Invasive nonfunctioning pituitary tumors (NFPTs) are non-resectable neoplasms associated with frequent relapse and significant comorbidities. Current treatments, including somatostatin receptor 2 (SSTR2)-directed somatostatin analogs (SSAs), often fail against NFPTs. Thus, identifying effective therapies is clinically relevant. As NFPTs express SSTR3 at high levels, pasireotide, a multireceptor-targeted SSA, might be beneficial. Here we evaluated pasireotide in the only representative model of spontaneous NFPTs (MENX rats) in vivo. Octreotide long-acting release (LAR), pasireotide LAR, or placebo, were administered to age-matched, tumor-bearing MENX rats of both sexes for 28 d or 56 d. Longitudinal high-resolution magnetic resonance imaging monitored tumor growth. While tumors in placebo-treated rats increased in volume over time, PTs in drug-treated rats displayed significant growth suppression, and occasional tumor shrinkage. Pasireotide elicited stronger growth inhibition. Radiological responses correlated with tumors’ proliferation rates. Both SSAs, but especially pasireotide, were more effective in female vs. male rats. Basal Sstr3 expression was significantly higher in the former group. It is noteworthy that female human NFPTs patients also have a trend towards higher SSTR3 expression. Altogether, our studies provide the rationale for testing pasireotide in patients with residual/recurrent NFPTs. If confirmed, the sex-related SSTR3 expression might be used as criteria to stratify NFPTs patients for treatment with pasireotide.
Reference Key
gulde2021cancersgender-specific Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Sebastian Gulde;Tobias Wiedemann;Mathias Schillmaier;Isabel Valença;Amelie Lupp;Katja Steiger;Hsi-Yu Yen;Stephen Bäuerle;Johannes Notni;Raul Luque;Herbert Schmid;Stefan Schulz;Donna P. Ankerst;Franz Schilling;Natalia S. Pellegata;Gulde, Sebastian;Wiedemann, Tobias;Schillmaier, Mathias;Valença, Isabel;Lupp, Amelie;Steiger, Katja;Yen, Hsi-Yu;Bäuerle, Stephen;Notni, Johannes;Luque, Raul;Schmid, Herbert;Schulz, Stefan;Ankerst, Donna P.;Schilling, Franz;Pellegata, Natalia S.;
Journal Cancers
Year 2021
DOI
10.3390/cancers13123097
URL
https://www.mdpi.com/2072-6694/13/12/3097
Keywords
MRI octreotide nonfunctioning pituitary tumors pasireotide somatostatin receptors sex differences in drug response

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.